
Hidden in plain sight
Tolerogenic dendritic cells offer a niche for human cytomegalovirus

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Tolerogenic dendritic cells offer a niche for human cytomegalovirus

Researchers investigate the impact on the immune system.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Rahmel-Stein K, Becker J, Lange B, Krajewski L, Eiz-Vesper B, Kalinke U
Obara M, Shandheep A, Rahmel-Stein K, Bruhn M, Costa B, Sujariyakul P, Pavlou A, Busker L, Hook S, Tamm S, Lange B, Schröder L, Kamp J, Stanke F, Ott M, Kalinke U
Grondman I, Koeken V, Couwenbergh T, Karageorgos A, Li W, Antonakos N, Zhang B, Damoraki G, van der Heijden W, Xu C, Giamarellos-Bourboulis E, Li Y, Netea M
The project investigates the factors that determine the species barrier mechanism of HCV and make it impossible to study the infection in animal models. The aim is to use genetic screening systems to develop in vivo models for vaccine research.
The CoViPa consortium uses computer-assisted high-throughput virus discovery and evolutionary analyses to identify RNA viruses with high spillover risk and potential animal host reservoirs and to investigate new pathogenicity factors.
By applying statistical genetics methods to pathogen genome sequences, we aim to identify and validate genetic determinants of phenotypes such as pathogenicity, virulence and antibiotic resistance, e.g. in E. coli and P. aeruginosa.
Monoclonal antibodies are transforming modern medicine. At Helmholtz Infection Medicine at MHH, bringing together TWINCORE and CiiM, advanced technologies and AI drive the development of next-generation human antibodies against major infectious diseases.
There are currently no events.

